RedHill Biopharma Ltd.
RHB-204
Crohn's disease
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for RHB-204 in Crohn's disease are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 14h ago
“Based on the FDA guidance on path to approval, RedHill’s novel Phase 2 RHB-204 study is designed to be the first-ever adequately controlled clinical study in a specifically defined MAP-positive CD patient population - a potentially paradigm”